Cheng Andrew's Form 4 filing
Akero Therapeutics, Inc. (AKRO) · filed Jul 11, 2025
- Accession no.
- 0000950170-25-095409
- Filed
- Jul 11, 2025
- Trade date
- Jul 10, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $1.53M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cheng AndrewCIK 0001778307 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 10, 2025 | Common Stock | SSaleDisposed | −14,686 | $50.57 | −$742,671.02 | 536,071 | Direct | |
| Jul 10, 2025 | Common Stock | SSaleDisposed | −15,314 | $51.73 | −$792,193.22 | 520,757 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.